Chimeric AAV Capsids Targeting Oligodendrocytes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adeno-associated virus (AAV) vectors predominantly target neurons rather than oligodendrocytes in the central nervous system, limiting their efficacy for treating disorders associated with oligodendrocyte dysfunction.
Innovation Solution
Development of chimeric AAV capsids with a specific tropism for oligodendrocytes, allowing for the creation of AAV vectors that efficiently transduce these cells, which involves modifying the AAV capsid sequence to enhance targeting and transduction efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional AAV vectors are used, then they efficiently transduce neurons, but they exhibit very low efficacy for transducing oligodendrocytes
Solution Approach 1:
The patent modifies specific regions of the AAV capsid protein sequence to alter cell type specificity. By making localized changes to the capsid structure (particularly in regions that interact with cell surface receptors), the vector gains the ability to selectively target oligodendrocytes while maintaining efficient transduction capability. This resolves the contradiction by creating vectors with differentiated targeting properties for different cell types.
Solution Approach 2:
The patent systematically varies parameters of the capsid protein sequence, including amino acid substitutions, deletions, and modifications at specific positions. By changing these sequence parameters, the invention generates AAV variants with altered tropism that can efficiently transduce oligodendrocytes, thereby resolving the limitation of conventional vectors that only efficiently target neurons.
2Reliability
If AAV capsid sequence is modified to target oligodendrocytes, then oligodendrocyte transduction efficiency improves, but vector design complexity increases
Solution Approach 1:
The patent divides the capsid protein sequence into distinct regions and modules, modifying specific segments while preserving others. This segmented approach allows systematic optimization of oligodendrocyte targeting without completely redesigning the entire vector, thereby managing design complexity while improving transduction efficiency.
Solution Approach 2:
The patent develops capsid variants that maintain multiple functions: oligodendrocyte targeting capability, efficient genome packaging, stable particle assembly, and appropriate immune evasion. By ensuring the modified capsid retains these universal AAV functions while adding oligodendrocyte specificity, the invention achieves improved efficiency without proportionally increasing overall design complexity.
Data Source
AI summary
The invention relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.